Related Experiment Video
Updated: Apr 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Surrogate-based LC-MS/MS quantification of endogenous creatinine in plasma, plasma-equivalent dried spots (qDPS), and
Arkadiusz Kocur1, Mateusz Moczulski1, Paulina Michalczuk1
1Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis. Medical University of Warsaw, 02-097 Warsaw, Poland.
Abstract:
Creatinine quantification in biological matrices remains analytically challenging due to its endogenous presence, which precludes the use of conventional external calibration methods. Concurrently, microsampling techniques such as plasma-equivalent dried plasma spots (qDPS) and volumetric absorptive microsampling (VAMS) are gaining increasing popularity for decentralized, low-volume, patient-centred sampling. Nevertheless, robust cross-matrix strategies for endogenous analytes remain limited. This study aimed to develop and validate an ICH M10-compliant LC-MS/MS method based on a surrogate analyte approach for creatinine determination in plasma, qDPS, and VAMS, and to assess analytical bridging between conventional plasma and microsamples. Calibration exhibited linearity over the range of 0.025-100 mg/L, with R² values of 0.9982, 0.9964, and 0.9971 for plasma, qDPS, and VAMS, respectively. Intra- and inter-day precision were ≤15% (≤20% at the LLOQ), and accuracy remained within ±15% at all quality control levels. Carryover was maintained within acceptable limits (<20% of the LLOQ for creatinine and <5% for the internal standard), while matrix-related variability was effectively controlled through isotopically labelled internal standardisation. Parallelism verified comparable analytical behaviour across matrices and hematocrit levels of 0.21-0.68 L/L. Creatinine remained stable in all matrices for 5 h at 60 °C, whereas microsamples preserved stability for up to 3 months under ambient, refrigerated, and frozen conditions. In a cohort of 61 renal transplant recipients, mean plasma creatinine concentrations were 1.57 mg/dL, 1.54 mg/dL in qDPS, and 1.26 mg/dL in VAMS. qDPS yielded plasma-equivalent concentrations without any need for recalculation, whereas VAMS necessitated regression-based correction (PLCRE = 1.197 × VAMSCRE+0.053). Collectively, these findings establish a validated surrogate-based LC-MS/MS platform for the precise measurement of creatinine across plasma and volumetric microsampling matrices, thereby providing a reliable analytical foundation for decentralized monitoring of renal function during transplant follow-up.
More Related Videos
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Related Concept Videos
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate